

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Rodriguez-Torres M, Jeffers LJ, Sheikh MY, et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. *N Engl J Med* 2009;360:257-67.

Supplementary Information

Guidelines for adjusting doses of peginterferon alfa-2a and ribavirin.

The dose of peginterferon alfa-2a was reduced if absolute neutrophil count (ANC) dropped to $<750/\text{mm}^3$ or if the platelet count dropped to $<50,000/\text{mm}^3$, and discontinued if ANC dropped to $<500/\text{mm}^3$ or the platelet count was $<25,000/\text{mm}^3$. Ribavirin dose was reduced in 200 mg/day decrements (to a lowest dose of 600 mg/day) for hemoglobin levels of 8.5–10 g/dL, or for patients with stable cardiovascular disease who experienced a fall in hemoglobin of ≥ 2 g/dL in any 4-week treatment period. The dose could be increased again at the clinician's discretion. Ribavirin was discontinued if hemoglobin decreased to <8.5 g/dL, or if a patient with stable cardiovascular disease maintained hemoglobin <10 g/dL despite 4 weeks of a reduced dose.

Table 1. SVR rates as a function of demographic and baseline characteristics for Latinos and non-Latinos.

Characteristic	Latino (n=269)		Non-Latino (n=300)	
	n	%	n	%
Country of origin				
Mexico	137	32.1	–	–
Puerto Rico	87	34.5	–	–
Cuba and others	45	35.6	–	–
Sex				
Male	183	32.8	192	53.1
Female	86	34.9	108	42.6
Age				
≤40 yr	75	40.0	49	59.2
>40 yr	194	30.9	251	47.4
BMI (kg/m ²)				
≤27	86	30.2	141	46.1
>27	175	35.4	152	52.6
BMI (kg/m ²)				
≤30	153	30.7	218	48.6
>30	108	38.0	75	52.0
ALT Quotient				
≤3 X ULN	203	36.5	250	46.0
>3 X ULN	66	24.2	50	66.0
HCV-RNA titers				
≤400,000 IU/mL	40	52.5	46	71.7
>400,000 IU/mL	229	30.1	254	45.3
HCV-RNA titers				
≤800,000 IU/mL	67	44.8	72	59.7
>800,000 IU/mL	202	29.7	228	46.1
Cirrhotic Classification				
Noncirrhotic	233	35.2	271	50.2
Cirrhotic	36	22.2	29	41.4

Table 2. Ribavirin and peginterferon alfa-2a dose reductions by weight quartiles

Weight (Quartiles)	<70.9 kg	≥70.9, <81.2 kg	≥81.2, <94.5 kg	≥94.5 kg	Total
Latino					
n	67	76	67	59	269
Patients with ribavirin dose reduction, n (%)	30 (44.8)	40 (52.6)	18 (26.9)	7 (11.9)	95 (35.3)
Patients with peginterferon alfa-2a dose reduction, n (%)	21 (31.3)	22 (28.9)	10 (14.9)	10 (16.9)	63 (23.4)
Non-Latino					
n	72	68	75	84	299
Patients with ribavirin dose reduction, n (%)	35 (48.6)	27 (39.7)	18 (24.0)	27 (32.1)	107 (35.8)
Patients with peginterferon alfa-2a dose reduction, n (%)	28 (38.9)	20 (29.4)	14 (18.7)	18 (21.4)	80 (26.8)

Fig. 1a. Ribavirin Dose Ranges.




Fig. 1b. Peginterferon Alfa-2a Dose Ranges.

